Search hospitals > Indiana > Elkhart

Midwest Cardiovascular Research and Education Foundation

Claim this profile
Elkhart, Indiana 46514
Conducts research for Heart Failure
Conducts research for Coronary Artery Disease
Conducts research for Hypertriglyceridemia
Conducts research for Cardiovascular Disease
Conducts research for Atrial Fibrillation
10 reported clinical trials
1 medical researcher
Photo of Midwest Cardiovascular Research and Education Foundation in ElkhartPhoto of Midwest Cardiovascular Research and Education Foundation in ElkhartPhoto of Midwest Cardiovascular Research and Education Foundation in Elkhart

Summary

Midwest Cardiovascular Research and Education Foundation is a medical facility located in Elkhart, Indiana. This center is recognized for care of Heart Failure, Coronary Artery Disease, Hypertriglyceridemia, Cardiovascular Disease, Atrial Fibrillation and other specialties. Midwest Cardiovascular Research and Education Foundation is involved with conducting 10 clinical trials across 17 conditions. There are 1 research doctors associated with this hospital, such as Troy Weirick, MD.

Top PIs

Clinical Trials running at Midwest Cardiovascular Research and Education Foundation

Heart Failure
Cardiovascular Disease
Type 2 Diabetes
High Blood Pressure
Coronary Artery Stenosis
Coronary Artery Disease
Aortic Stenosis
Von Willebrand Disease
Image of trial facility.

BI 690517 + Empagliflozin

for Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.
Recruiting1 award Phase 32 criteria
Image of trial facility.

Vicadrostat + Empagliflozin

for Heart Failure

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, helps people with chronic heart failure. In this study, participants are put into 2 groups randomly. Participants have an equal chance of being in either group. One group takes vicadrostat/empagliflozin tablets, and the other group takes placebo/empagliflozin tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take the study medicines as tablets once a day for between 1 and about 3.5 years. During this time, they can continue their regular treatment for heart failure. Participants can stay in the study as long as they benefit from treatment and can tolerate it, for a maximum of about 3.5 years. During this time, they visit the study site regularly. The exact number of visits is different for each participant, depending on how long they stay in the study. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The doctors document when participants experience worsening of their heart failure symptoms, must go to hospital due to heart failure, or die during the study. The time until these events are observed is compared between the treatment groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Recruiting1 award Phase 31 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Midwest Cardiovascular Research and Education Foundation?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security